The Board of Directors of Bactiguard Holding AB (publ.) has appointed Christine Lind as new CEO. Christine brings broad strategic and operational experience from more than 25 years in the healthcare sector. Previous assignments encompass positions in Swedish listed companies such as Mendus AB, XSPRAY PHARMA AB, and Medivir AB as well as senior advisory roles.

Prior to that, Christine spent a decade as an investment banker at Merrill Lynch. She joins Bactiguard at the beginning of May and assumes the role as CEO on 14 May 2024 in connection with the Annual General Meeting. The company thanked Thomas von Koch, on behalf of the entire Board of Directors, for his dedicated work and exceptional leadership during a critical time for Bactiguard.

Several challenging but crucial strategic decisions have been taken under his leadership and he has kick-started the transformation work which is now well underway. Thomas has showed what responsible ownership means and he will hand over the CEO responsibilities to Christine in a structured and coordinated manner, having the very best interest of Bactiguard and stakeholders in mind. Christine Lind was born in 1974 in the US and has lived in Sweden since 2015.

She holds a BSc in Finance & Information Systems from New York University and an MBA from Columbia Business School. Throughout her career, she has held CEO and executive level business development and strategy positions at biotech companies, including BioArctic AB, Medivir AB and LifeCell Corporation. Christine also spent a decade as an investment banker at Merrill Lynch in New York, advising biotech and pharma companies on licensing, M&A, and financing.

She comes most recently from a role as Senior Vice President Corporate Development at SSI Strategy/NDA Group AB.